1. Главная
  2. Ресурсы
  3. Библиотечный поиск
CYP2D6 Genotype andTamoxifen Response inPostmenopausal WomenwithEndocrine-ResponsiveBreast Cancer: TheBreast InternationalGroup 1-98 Trial Meredith M. ReganBrian Leyland‐JonesMark Bouzyk2012 год

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
статья из журнала

Полный текстСтраница публикацииПубликация в OpenAlex
Аннотация: BackgroundAdjuvant tamoxifen therapy is effective for postmenopausal women with endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes tamoxifen to clinically active metabolites, and CYP2D6 polymorphisms may adversely affect tamoxifen efficacy. In this study, we investigated the clinical relevance of CYP2D6 polymorphisms.
Год издания: 2012
Авторы: Meredith M. Regan, Brian Leyland‐Jones, Mark Bouzyk, Olivia Pagani, Weining Tang, Roswitha Kammler, Patrizia Dell’Orto, Maria Olivia Biasi, Beat Thürlimann, Maria Lyng, Henrik J. Ditzel, Patrick Neven, Marc Debled, Rudolf Maibach, Karen N. Price, Richard D. Gelber, Alan S. Coates, Aron Goldhirsch, James M. Rae, Giuseppe Viale
Издательство: Oxford University Press
Источник: JNCI Journal of the National Cancer Institute
Ключевые слова: Estrogen and related hormone effects, Pharmacogenetics and Drug Metabolism, Inflammatory mediators and NSAID effects
Другие ссылки: JNCI Journal of the National Cancer Institute (PDF)
JNCI Journal of the National Cancer Institute (HTML)
Europe PMC (PubMed Central) (PDF)
Europe PMC (PubMed Central) (HTML)
BORIS (University Library Bern) (PDF)
BORIS (University Library Bern) (HTML)
RERO DOC (Universität Bern) (HTML)
PubMed Central (HTML)
PubMed (HTML)